Literature DB >> 33459509

Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.

Hai Yu1,2, Duanni Zhang3, Minxue Lian1.   

Abstract

INTRODUCTION: Glioma is the most common malignant primary brain tumor with survival outcome for patients with lower-grade gliomas (LGGs) being quite variable. Epigenetic modifications in LGGs appear tightly linked to patient clinical outcomes but are not commonly used as clinical tools. AIMS: We aimed to derive an epigenetic enzyme gene signature for LGGs that would allow for improved clinical risk stratification.
RESULTS: The study employed transcriptomic data of 711 lower-grade gliomas from three publically available data sets. Based on least absolute shrinkage and selection operator (LASSO) Cox regression analysis, we discovered a 13-gene epigenetic signature that strongly predicts poor overall survival in LGGs. The robust prediction ability for survival was further verified in two independent validation cohorts. The signature was also significantly associated with malignant molecular signatures including wild-type IDH, unmethylated MGMT promoter, and non-codeletion of 1p19q together with linkage to multiple oncogenic pathways. Interestingly, our results showed that immune infiltration of MDSCs together with mRNA expression of immune inhibition biomarkers was also positively correlated with the epigenetic signature. Lastly, we confirmed the oncogenic role of SMYD2 in glioma tumor cells in functional assays.
CONCLUSIONS: We report a novel epigenetic gene signature that harbors robust survival prediction value for LGG patients that is tightly linked to activation of multiple oncogenic pathways.
© 2021 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  epigenetic signature; immune suppression; lower-grade gliomas; overall survival; risk stratification

Mesh:

Year:  2021        PMID: 33459509      PMCID: PMC7941239          DOI: 10.1111/cns.13587

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  49 in total

1.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Authors:  Daniel J Brat; Roel G W Verhaak; Kenneth D Aldape; W K Alfred Yung; Sofie R Salama; Lee A D Cooper; Esther Rheinbay; C Ryan Miller; Mark Vitucci; Olena Morozova; A Gordon Robertson; Houtan Noushmehr; Peter W Laird; Andrew D Cherniack; Rehan Akbani; Jason T Huse; Giovanni Ciriello; Laila M Poisson; Jill S Barnholtz-Sloan; Mitchel S Berger; Cameron Brennan; Rivka R Colen; Howard Colman; Adam E Flanders; Caterina Giannini; Mia Grifford; Antonio Iavarone; Rajan Jain; Isaac Joseph; Jaegil Kim; Katayoon Kasaian; Tom Mikkelsen; Bradley A Murray; Brian Patrick O'Neill; Lior Pachter; Donald W Parsons; Carrie Sougnez; Erik P Sulman; Scott R Vandenberg; Erwin G Van Meir; Andreas von Deimling; Hailei Zhang; Daniel Crain; Kevin Lau; David Mallery; Scott Morris; Joseph Paulauskis; Robert Penny; Troy Shelton; Mark Sherman; Peggy Yena; Aaron Black; Jay Bowen; Katie Dicostanzo; Julie Gastier-Foster; Kristen M Leraas; Tara M Lichtenberg; Christopher R Pierson; Nilsa C Ramirez; Cynthia Taylor; Stephanie Weaver; Lisa Wise; Erik Zmuda; Tanja Davidsen; John A Demchok; Greg Eley; Martin L Ferguson; Carolyn M Hutter; Kenna R Mills Shaw; Bradley A Ozenberger; Margi Sheth; Heidi J Sofia; Roy Tarnuzzer; Zhining Wang; Liming Yang; Jean Claude Zenklusen; Brenda Ayala; Julien Baboud; Sudha Chudamani; Mark A Jensen; Jia Liu; Todd Pihl; Rohini Raman; Yunhu Wan; Ye Wu; Adrian Ally; J Todd Auman; Miruna Balasundaram; Saianand Balu; Stephen B Baylin; Rameen Beroukhim; Moiz S Bootwalla; Reanne Bowlby; Christopher A Bristow; Denise Brooks; Yaron Butterfield; Rebecca Carlsen; Scott Carter; Lynda Chin; Andy Chu; Eric Chuah; Kristian Cibulskis; Amanda Clarke; Simon G Coetzee; Noreen Dhalla; Tim Fennell; Sheila Fisher; Stacey Gabriel; Gad Getz; Richard Gibbs; Ranabir Guin; Angela Hadjipanayis; D Neil Hayes; Toshinori Hinoue; Katherine Hoadley; Robert A Holt; Alan P Hoyle; Stuart R Jefferys; Steven Jones; Corbin D Jones; Raju Kucherlapati; Phillip H Lai; Eric Lander; Semin Lee; Lee Lichtenstein; Yussanne Ma; Dennis T Maglinte; Harshad S Mahadeshwar; Marco A Marra; Michael Mayo; Shaowu Meng; Matthew L Meyerson; Piotr A Mieczkowski; Richard A Moore; Lisle E Mose; Andrew J Mungall; Angeliki Pantazi; Michael Parfenov; Peter J Park; Joel S Parker; Charles M Perou; Alexei Protopopov; Xiaojia Ren; Jeffrey Roach; Thaís S Sabedot; Jacqueline Schein; Steven E Schumacher; Jonathan G Seidman; Sahil Seth; Hui Shen; Janae V Simons; Payal Sipahimalani; Matthew G Soloway; Xingzhi Song; Huandong Sun; Barbara Tabak; Angela Tam; Donghui Tan; Jiabin Tang; Nina Thiessen; Timothy Triche; David J Van Den Berg; Umadevi Veluvolu; Scot Waring; Daniel J Weisenberger; Matthew D Wilkerson; Tina Wong; Junyuan Wu; Liu Xi; Andrew W Xu; Lixing Yang; Travis I Zack; Jianhua Zhang; B Arman Aksoy; Harindra Arachchi; Chris Benz; Brady Bernard; Daniel Carlin; Juok Cho; Daniel DiCara; Scott Frazer; Gregory N Fuller; JianJiong Gao; Nils Gehlenborg; David Haussler; David I Heiman; Lisa Iype; Anders Jacobsen; Zhenlin Ju; Sol Katzman; Hoon Kim; Theo Knijnenburg; Richard Bailey Kreisberg; Michael S Lawrence; William Lee; Kalle Leinonen; Pei Lin; Shiyun Ling; Wenbin Liu; Yingchun Liu; Yuexin Liu; Yiling Lu; Gordon Mills; Sam Ng; Michael S Noble; Evan Paull; Arvind Rao; Sheila Reynolds; Gordon Saksena; Zack Sanborn; Chris Sander; Nikolaus Schultz; Yasin Senbabaoglu; Ronglai Shen; Ilya Shmulevich; Rileen Sinha; Josh Stuart; S Onur Sumer; Yichao Sun; Natalie Tasman; Barry S Taylor; Doug Voet; Nils Weinhold; John N Weinstein; Da Yang; Kosuke Yoshihara; Siyuan Zheng; Wei Zhang; Lihua Zou; Ty Abel; Sara Sadeghi; Mark L Cohen; Jenny Eschbacher; Eyas M Hattab; Aditya Raghunathan; Matthew J Schniederjan; Dina Aziz; Gene Barnett; Wendi Barrett; Darell D Bigner; Lori Boice; Cathy Brewer; Chiara Calatozzolo; Benito Campos; Carlos Gilberto Carlotti; Timothy A Chan; Lucia Cuppini; Erin Curley; Stefania Cuzzubbo; Karen Devine; Francesco DiMeco; Rebecca Duell; J Bradley Elder; Ashley Fehrenbach; Gaetano Finocchiaro; William Friedman; Jordonna Fulop; Johanna Gardner; Beth Hermes; Christel Herold-Mende; Christine Jungk; Ady Kendler; Norman L Lehman; Eric Lipp; Ouida Liu; Randy Mandt; Mary McGraw; Roger Mclendon; Christopher McPherson; Luciano Neder; Phuong Nguyen; Ardene Noss; Raffaele Nunziata; Quinn T Ostrom; Cheryl Palmer; Alessandro Perin; Bianca Pollo; Alexander Potapov; Olga Potapova; W Kimryn Rathmell; Daniil Rotin; Lisa Scarpace; Cathy Schilero; Kelly Senecal; Kristen Shimmel; Vsevolod Shurkhay; Suzanne Sifri; Rosy Singh; Andrew E Sloan; Kathy Smolenski; Susan M Staugaitis; Ruth Steele; Leigh Thorne; Daniela P C Tirapelli; Andreas Unterberg; Mahitha Vallurupalli; Yun Wang; Ronald Warnick; Felicia Williams; Yingli Wolinsky; Sue Bell; Mara Rosenberg; Chip Stewart; Franklin Huang; Jonna L Grimsby; Amie J Radenbaugh; Jianan Zhang
Journal:  N Engl J Med       Date:  2015-06-10       Impact factor: 91.245

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  SMYD2 suppresses APC2 expression to activate the Wnt/β-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.

Authors:  Fanchao Meng; Xin Liu; Changwei Lin; Lei Xu; Jinjin Liu; Pengbo Zhang; Xiuzhong Zhang; Jun Song; Yichao Yan; Zeqiang Ren; Yi Zhang
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

5.  Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.

Authors:  Xun Jin; Leo J Y Kim; Qiulian Wu; Lisa C Wallace; Briana C Prager; Tanwarat Sanvoranart; Ryan C Gimple; Xiuxing Wang; Stephen C Mack; Tyler E Miller; Ping Huang; Claudia L Valentim; Qi-Gang Zhou; Jill S Barnholtz-Sloan; Shideng Bao; Andrew E Sloan; Jeremy N Rich
Journal:  Nat Med       Date:  2017-10-09       Impact factor: 53.440

6.  Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.

Authors:  Anne Dirkse; Anna Golebiewska; Thomas Buder; Petr V Nazarov; Arnaud Muller; Suresh Poovathingal; Nicolaas H C Brons; Sonia Leite; Nicolas Sauvageot; Dzjemma Sarkisjan; Mathieu Seyfrid; Sabrina Fritah; Daniel Stieber; Alessandro Michelucci; Frank Hertel; Christel Herold-Mende; Francisco Azuaje; Alexander Skupin; Rolf Bjerkvig; Andreas Deutsch; Anja Voss-Böhme; Simone P Niclou
Journal:  Nat Commun       Date:  2019-04-16       Impact factor: 14.919

7.  Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.

Authors:  Hai Yu; Duanni Zhang; Minxue Lian
Journal:  CNS Neurosci Ther       Date:  2021-01-18       Impact factor: 5.243

8.  Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.

Authors:  Xiao-Yang Liu; Noha Gerges; Andrey Korshunov; Nesrin Sabha; Dong-Anh Khuong-Quang; Adam M Fontebasso; Adam Fleming; Djihad Hadjadj; Jeremy Schwartzentruber; Jacek Majewski; Zhifeng Dong; Peter Siegel; Steffen Albrecht; Sidney Croul; David T W Jones; Marcel Kool; Martje Tonjes; Guido Reifenberger; Damien Faury; Gelareh Zadeh; Stefan Pfister; Nada Jabado
Journal:  Acta Neuropathol       Date:  2012-08-12       Impact factor: 15.887

9.  Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma.

Authors:  Shan-Ru Zuo; Xiao-Cong Zuo; Yang He; Wei-Jin Fang; Chun-Jiang Wang; Heng Zou; Pan Chen; Ling-Fei Huang; Li-Hua Huang; Hong Xiang; Shi-Kun Liu
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

10.  PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors:  Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more
  6 in total

1.  STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells.

Authors:  Kailing Pan; Bin Hu; Lude Wang; Jianlie Yuan; Wenxia Xu
Journal:  J Mol Neurosci       Date:  2022-08-08       Impact factor: 2.866

2.  PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas.

Authors:  Qijun Xie; Xianlong Huang; Wu Huang; Fang Liu
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

3.  Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.

Authors:  Hai Yu; Duanni Zhang; Minxue Lian
Journal:  CNS Neurosci Ther       Date:  2021-01-18       Impact factor: 5.243

4.  The Role of m5C-Related lncRNAs in Predicting Overall Prognosis and Regulating the Lower Grade Glioma Microenvironment.

Authors:  Hongshu Zhou; Ming Meng; Zeyu Wang; Hao Zhang; Liting Yang; Chuntao Li; Liyang Zhang
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

Review 5.  Mechanistic and functional extrapolation of SET and MYND domain-containing protein 2 to pancreatic cancer.

Authors:  Eid Alshammari; Ying-Xue Zhang; Zhe Yang
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

6.  Glycosylation modification patterns reveal distinct tumor metabolism and immune microenvironment landscape in lower-grade gliomas.

Authors:  Guihua Tang; Liming Tan; Hao Yuan; Wen Yin
Journal:  Front Cell Dev Biol       Date:  2022-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.